Zila, Inc. (ZILAD) Reports a Q4 Loss
Zila, Inc. (Nasdaq: ZILAD) reported financial results for its fiscal 2008 fourth quarter.
Net revenues increased 14% to $11.9 million compared with $10.4 million for the fourth quarter of fiscal 2007. (Consensus is $11.20 million)
Loss from continuing operations significantly narrowed to $2.4 million, or $0.26 per share, from a loss from continuing operations of $5.8 million, or $0.65 per share, for the fourth quarter of fiscal 2007. (Consensus is a loss of $0.28 - only 1 analyst)
Zila, Inc., a specialty pharmaceutical company, focuses on the prevention, detection, and treatment of oral diseases, primarily oral cancer. [SM]
Net revenues increased 14% to $11.9 million compared with $10.4 million for the fourth quarter of fiscal 2007. (Consensus is $11.20 million)
Loss from continuing operations significantly narrowed to $2.4 million, or $0.26 per share, from a loss from continuing operations of $5.8 million, or $0.65 per share, for the fourth quarter of fiscal 2007. (Consensus is a loss of $0.28 - only 1 analyst)
Zila, Inc., a specialty pharmaceutical company, focuses on the prevention, detection, and treatment of oral diseases, primarily oral cancer. [SM]
You May Also Be Interested In
- UPDATE: Bristow Group (BRS) Reports Better-Than-Expected Q4 Results; Offers FY13 Outlook
- Infoblox (BLOX) Tops Q3 EPS by 4c; Guides Q4
- Taro Pharmaceutical Industries (TARO) Nearly Doubles Q1 EPS to 1.06
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
